Vaccibody.com | News
8
blog,paged,paged-6,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-16.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.5.5,vc_responsive

In a private share issue placement in June Vaccibody raised 733.000 € from existing owners. The funding will be allocated to the company’s development of VB10.16, a therapeutic vaccine against cervical cancer. During the last 6 months Vaccibody has obtained significant progression with conclusive data in...

Vaccibody CSO, Agnete Fredriksen together with Professor Bjarne Bogen and Inger Sandlie published a review in Frontiers in Tumor Immunity. "Targeted DNA vaccines for enhanced induction of Idiotype (Id)-specific B and T cells" is available for download here....

Vaccibody raises 875 000 € in new share issues. The Norwegian Radium Hospital Research Foundation and Sarsia Seed together invested € 760 000 and additional 9 investors added € 115 000 in the share issue held June 28th. “This successful share issue allows us to...

A report addressing solutions for strengthening the Norwegian biotechindustry was handed over to the Norwegian government May 20th. Vaccibody was the company being exemplified in the accompanying article in Dagens Næringsliv. Read the article here (Norwegian only)....

The European Life Science CEO forum, Zürich March 6-7 BIO Europe Spring, Amsterdam  March 19-21 Anglo Nordic Biotech Conference. London May 24. EPIC ,London May 31. 2012 BIO international convention, Boston June 18-21 ...

Vaccibody is the only Norwegian partner in the large EU-project, ADITEC. More information on the project is now launched at this site: http://www.aditecproject.eu/ ...